" the six patients were heavily pre-treated and had received a median of four prior lines of AML treatment (range 2 - 8)." "...Three patients 1 CR and 2 PR were bridged..transplant.Of note: these three patients had all received less than five prior line of treatment...."
Logically from the above notes, I would assume that in EMD AML trial which RAC has totally control including the right to select the most suitable clinical patients for this trial and therefore the patients with 2 pre-treated or less would be ideal AIMO
